Health · 1 sources covering this

STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year

Prescription drugs purchased under a controversial government discount program amounted to $100 billion in 2025, a 22.8% increase from the previous year.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·3h ago
STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year
Prescription drugs purchased under a controversial government discount program amounted to $100 billion in 2025, a 22.8% increase from the previous year.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/d4c5192a29be7db1ab42e23a8e0ab5ef128b70dd"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year"></iframe>

STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year

How 1 sources are covering this

STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year

More from Health

STAT+: FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access

As cyclospora illnesses surge to a record, Michigan officials eye lettuce as a possible cause

STAT+: Top Democrats question RFK Jr.’s health care advisory panel

STAT+: Hospital chain HCA warns of lower profits as more patients go uninsured

Reader

Trust & legal

Across the network